Tony Hagen

Experts focus on genetic abnormalities to advance cancer care.

Researchers find that women with postmenopausal hormone receptor (HR)-positive breast cancer may undergo shorter treatments of Arimidex, which may in turn cause less bone fractures.

The combination use of Herceptin plus standard adjuvant chemotherapy does not improve outcomes in women with HER2-low breast cancer.

As PARP inhibitors continue to improve outcomes in patients with ovarian cancer, they may one day be moved into the frontline treatment setting, said Susana M. Campos, M.D., a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School.

The newly approved CAR T-cell therapy, Kymriah (tisagenlecleucel), is being put on the market with a price tag of $475,000 for a single infusion, which is within the range that oncologists predicted.

“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, M.D., a co-author of the statement, and immediate past chair of ASCO’s government relations committee.

Reforms are needed high up within the drug distribution chain, concluded a panel of pharmaceutical professionals at the Oncology Market Access & Pricing conference held in Philadelphia this week by eyeforpharma.

The American Health Care Act has been passed by a vote of 217 to 213.

Can President Donald Trump be more successful in lowering drug prices than he was in repealing and replacing the Affordable Care Act?

Tecentriq showed impressive long-term survival in patients with metastatic TNBC, according to the results from a recent study.

Oncological societies see President Donald Trump’s fiscal year 2018 budget proposal as a huge potential setback to health efforts in the fight against cancer.

The FDA expanded Avastin's approval to include patients with platinum-sensitive ovarian cancer.

Breast cancer survivor and news anchor Amy Robach delivered a compelling keynote address at the 33rd Annual Miami Breast Cancer Conference® that was as hard-hitting as it was emotional.

Before losing her battle to ovarian cancer, Julie Paige McAvinn wanted to make sure other women were better educated about female cancers. Keeping his promise to his late wife, Peter McAvinn created the Julie Fund.

Nexavar and Lenvima have significantly altered the treatment paradigm for patients with advanced RAI-refractory differentiated thyroid cancer, with combination strategies hoping to further build upon this success.

If obese when diagnosed, women with certain breast cancers face a higher risk of recurrence — but they still have time to change that outlook.

Oncology experts supported a patient-driven online petition asking Congress to give the government, patients and other stakeholders more power when it comes to negotiating prices for cancer drugs.

Clinical development of prostate cancer vaccines is moving forward.

By allowing oncologists to better understand treatment patterns and options, a new big-data system aims to ensure that patients will benefit from the most informed medical decisions as they fight cancer.

The possibility of going bankrupt is high on the list of concerns for more than a third of cancer patients who participated in a recently published survey by the Cancer Support Community.

Expanded access programs are run in conjunction with late-stage clinical trials so that promising investigational drugs can get into the hands of patients who stand a good chance of benefiting from them, and who have exhausted their other treatment options, including clinical trials.

What does it take for patients with cancer who have exhausted their other medical options to gain access to late-stage investigational drugs?

Through expanded access programs, patients with cancer—unable to join clinical trials—benefit from investigational drugs.